Diagnostic utility of plasma p‐tau217 differs by Alzheimer's disease tau‐based subtypes
Plasma phosphorylated tau (p-tau)217 differentiated cognitively unimpaired from impaired individuals in most subtypes, with the notable limitation of the medial temporal lobe (MTL)-sparing group.P-tau217 level was linked to regional tau accumulation as measured by tau positron emission tomography, across all subtypes.The MTL-sparing subtype appeared to be unique, as p-tau217 was not elevated in cognitively impaired individuals, and there was no clear relationship between p-tau217 levels and cognitive performance.
Authors
- Ali Reihanian (ORCID: https://orcid.org/0000-0001-6668-3535)
- Gloria Chia-Yi Chiang (ORCID: https://orcid.org/0000-0001-9925-0816)
- Krista Minéia Wartchow (ORCID: https://orcid.org/0000-0003-4572-3600)
- Liangdong Zhou (ORCID: https://orcid.org/0000-0002-8389-274X)
- William Jones Dartora (ORCID: https://orcid.org/0000-0002-6164-0031)
- Laura Beth McIntire (ORCID: https://orcid.org/0000-0002-9565-8889)
- Shahram Zare
- Tracy Butler (ORCID: https://orcid.org/0000-0003-0130-8122)
- Nancy S. Foldi (ORCID: https://orcid.org/0000-0001-8810-8558)
- Mohammad Khalafi (ORCID: https://orcid.org/0000-0002-9447-5167)
- Yi Li (ORCID: https://orcid.org/0000-0002-3875-3513)
- Sudhin A. Shah (ORCID: https://orcid.org/0000-0003-4116-1989)
- Hasan Jafari
- Seyed Hani Hojjati (ORCID: https://orcid.org/0000-0003-3900-9603)
Institutions
- Cornell University (US)
- Arak University (IR)
- Babol Noshirvani University of Technology (IR)
Publication Details
- Journal
- Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/dad2.70227
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Eisai
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- Canadian Institutes of Health Research